75438-54-9

Basic information

• Product Name: 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE
• Synonyms: 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE;4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLINE-2-YL)-AMINOPYRIDINE;1-Acetyl-2-[(4,6-dichloro-2-methylpyrimidin-5-yl)amino]-4,5-dihydro-1H-imidazole, 5-[(1-Acetyl-4,5-dihydro-1H-imidazol-2-yl)amino]-4,6-dichloro-2-methylpyrimidine;Ethanone,1-[2-[(4,6-dichloro-2-Methyl-5-pyriMidinyl)aMino]-4,5-dihydro-1H-iMidazol-1-yl]-;1-Acetyl-N-(4,6-dichloro-2-methyl-5-pyrimidinyl)-4,5-dihydro-1H-imidazol-2-amine;1-(2-((4,6-Dichloro-2-MethylpyriMidin-5-yl)aMino)-4,5-dihydro-1H-iMidazol-1-yl)ethanone
• CAS NO: 75438-54-9
• Molecular Formula: C₁₀H₁₁Cl₂N₅O
• Molecular Weight: 288.13
• EINECS: 200-258-5
• Mol File: 75438-54-9.mol

Chemical Properties

• Boiling Point: 394.7 °C at 760 mmHg
• Flash Point: 192.5 °C
• Appearance: /
• Density: 1.59±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• PKA: 0.41±0.20(Predicted)
• CAS DataBase Reference: 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE(75438-54-9)
• EPA Substance Registry System: 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE(75438-54-9)

Safety Data

• Hazardous Substances Data: 75438-54-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE is used as a key intermediate in the synthesis of Moxonidine-13C,d3 (M745803), a labelled antihypertensive agent. 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE plays a crucial role in the development of new drugs for the treatment of hypertension, a common cardiovascular condition that affects millions of people worldwide.
In the synthesis process, 4,6-DICHLORO-2-METHYL-5-(1-ACETYL-2-IMIDAZOLIN-2-YL)-AMINOPYRIDINE is transformed into Moxonidine-13C,d3, which is a stable isotope-labelled version of the original drug Moxonidine. This labelled compound can be used for various purposes, such as studying the drug's metabolism, pharmacokinetics, and pharmacodynamics, as well as for diagnostic and research applications.
Furthermore, the development of Moxonidine-13C,d3 as a labelled antihypertensive agent can potentially lead to improved understanding of the drug's mechanism of action, optimization of its therapeutic effects, and reduction of side effects. This, in turn, can contribute to the advancement of hypertension treatment and management strategies, ultimately benefiting patients and healthcare providers alike.

Upstream product

• 39906-04-2 5-amino-4,6-dichloro-2-methylpyrimidine 
• 5391-39-9 1-acetylimidazolidin-2-one 
• 438000-58-9 1-[1-((4,6-dichloro-2-methyl-pyrimidin-5-yl)imino)-ethyl]-imidazolidin-2-one 

Downstream Products

• 352457-35-3 4,6-dichloro-2-methyl-5-(2-imidazolin-2-yl)-aminopyrimidine 
• 75439-01-9 4,6-dimethoxy-2-methyl-5-(2-imidazolin-2-yl)-aminopyrimidine 
• 75438-57-2 moxonidine 
• 75438-55-0 4-chloro-2-methyl-6-methylthio-5-(2-imidazolin-2-yl)-aminopyrimidine 
• 75438-59-4 4,6-di-methylthio-2-methyl-5-(2-imidazolin-2-yl)-aminopyrimidine 
• 75438-91-4 4-chloro-6-ethoxy-2-methyl-5-(2-imidazolin-2-yl)-aminopyrimidine 
• 1033401-62-5 1-[1-[(4-chloro-2-methyl-6-methoxy-pyrimidin-5-yl)imino]ethyl]-imidazolidin-2-one 
• 438000-58-9 1-[1-((4,6-dichloro-2-methyl-pyrimidin-5-yl)imino)-ethyl]-imidazolidin-2-one 

Relevant articles and documents

Process for the preparation of moxonidine

The present invention provides an improved process for the preparation of 4,6-dichloro-2-methyl-5-(1-acetyl-2-imidazolin-2-yl)aminopyrimidine. The present invention also provides an improved process for the preparation of moxonidine. The present invention further provides a process for the purification of moxonidine.

MOXONIDINE ANALOGS, PREPARATION PROCESSES AND USES THEREFOR

The present invention provides derivatives of moxonidine, 1-[l-[(4,6-dichloro-2-methyl-6-5-pyrimidinyl)imino]ethyl]-2-imidazolidinone of formula (V) and l-[l-[(4-chloro-2-methyl-6-methoxy-5-pyrimidinyl)imino]ethyl]-2-imidazolidinone of formula (VI), which can be used for testing the purity or monitoring the production of moxonidine, and process for preparing the derivatives. Also provided is an improved process for preparing 4,6- dichloro-2-methyl-5-(l-acetyl-2-imidazolin-2-yl)-aminopyrimidine (DMAIA) and a method of utilizing the process to produce moxonidine.

Substituted aminopyrimidines

The present invention is directed to certain aminopyrimidines of the general formula STR1 wherein R1, R2, and R3 are hydrogen, halogen, alkoxy, alkylthio, or alkyl having 1 to 4 carbon atoms, or cycloalkyl having 3 to 5 carbon atoms and R4 is hydrogen or an aliphatic or aromatic acyl group, as well as physiologically compatible acid addition salts thereof. Compounds of the present invention are useful as blood pressure lowering agents and in the treatment of glaucoma.